Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Meet us at AACR 2026 - April 17-22 - TME Interplay with Organoids
Search
MyLab About Us Contact
Lambda Biologics
Languages
Get a Quote
Close button
Faster clinically relevant insights

Antibody-Drug Conjugate (ADC) Evaluation Platform

Lambda Biologics enables the robust evaluation of complex therapeutic modalities by offering optimized preclinical models for antibody-drug conjugates (ADCs) and bispecific antibodies that are aligned with the latest FDA and EMA regulatory expectations.
Contact us

Human Organoid-Based Evaluation Platform for ADC Efficacy and Toxicit Prediction

Antibody-Drug Conjugates (ADCs) represent a powerful paradigm shift in oncology. By combining the precision of targeted antibodies with highly potent cytotoxic payloads, ADCs deliver chemotherapy directly to cancer cells while sparing healthy tissue. However, developing effective and safe ADCs remains highly challenging due to several critical issues:

  • Uneven target antigen expression within tumors
  • Poor penetration of large ADC molecules into solid tumors
  • Narrow therapeutic window and risk of off-target toxicity
  • Multiple resistance mechanisms (antigen loss, impaired internalization, and drug efflux)

Critical problems that occur during ADC development

  • On-target toxicity in normal tissues: Antibody binds to target on both cancer and healthy cells, causing damage.
  • Payload-driven systemic toxicity: Toxic drug (payload) leaks and affects the whole body.
  • Differential target expression: Target protein is expressed differently between tumors and normal tissues.
  • Bystander effect: Released drug kills neighboring cells (can be useful or harmful).

Cell Line-based Models (2D)

  • Flat 2D culture does not mimic real tissue structure.
  • Lacks proper microenvironment (no blood vessels, immune cells, or matrix).
  • Target expression differs from real human tissues.
  • Poor at reproducing ADC internalization and drug release.

Animal Models

  • Species differences in antigen expression and drug metabolism.
  • Poor cross-reactivity with human-specific antibodies.
  • Difficult to predict human organ-specific toxicity.

Human Organoid-based Systems (3D) *

  • Preserves natural 3D tissue architecture and cellular composition.
  • Maintains realistic target antigen expression in both normal and tumor tissues.
  • Allows side-by-side testing of efficacy and toxicity using human cells.
  • Better represents tumor microenvironment and 3D conditions.
* Benefits of Human Organoid-based platform compared with traditional cell-lines or animal model for ADC development

Cultured directly from patient tumor biopsies, our patient-derived organoids (PDOs) preserve the tumor’s genetic fidelity and phenotypic traits with high fidelity. By overcoming the limitations of traditional 2D cell lines and animal models, Lambda Biologics’ PDOs provide highly clinically relevant platforms that enable more accurate prediction of drug efficacy and patient response through:

  • Patient-derived cancer organoids from colorectal, breast, gastric, pancreatic, hepatocellular, lung, and additional indications – strategically aligned with major ADC target cancers
  • Tumor microenvironment (TME) co-culture systems integrating cancer-associated fibroblasts (CAFs), macrophages, and T cells to accurately model stromal barriers and immune interactions that influence ADC penetration and efficacy
  • Comprehensive Organoid Toxicity Panel for multi-parameter toxicity evaluation, including structural damage in normal organoids, elevated toxicity markers, and organ-specific toxicity profiling
  • Advanced spatial biology and molecular profiling using PhenoCycler, CosMx, and scRNA-seq for high-resolution mapping of antigen expression, drug distribution, and therapeutic response within complex organoid tissues
Target expression was evaluated by flow cytometry in 10 CRC, 9 LC, and 9 PC lines. The graphs summarize expression levels by cancer type and demonstrate heterogeneous expression across lines.

Organoid-Based ADC Efficacy & Toxicity Evaluation Workflow

Cell Line-based Models (2D)

(Based on target expression database)
  • Tumor organoid selection
  • Normal organoid selection

Efficacy Evaluation in Tumor Organoids

  • Image-based analysis
  • FACS-based analysis
  • CellTiter-Glo

Toxicity Evaluation in Normal Organoids

  • Histology analysis
  • Normal organoid selection

Contact us to discuss your
antibody-drug conjugate (ADC) development project

Human Organoid-Based Evaluation Platform for ADC Efficacy and Toxicity Prediction
Contact us

Explore Lambda Biologics Services

Organoid Service

Specialized organoid-based assays for modeling human biology in vitro—designed to enhance predictive accuracy in drug response, toxicity, and disease progression.

Disease ModelingView AllUpdated

Research Service

Custom in vitro studies leveraging organoid and cell-based models to support hypothesis-driven research, mechanistic validation, and translational insights.

CosmeticsView All OECD TGView All ZebrafishView All

Technical Service

Advanced analytical support including molecular profiling, spatial biology, and imaging—enabling precise characterization of organoid and cell-based systems.

Molecular BiologyView All BioinfomaticsView All Spatial BiologyView All Live&3D ImagingView All

Thank you for your insterest

You can now download the file.
Download now
Return to Homepage

Connect with Us